Join GT Biopharma for a virtual KOL event featuring Jeffrey Miller, MD¹ and Mark Juckett, MD from the University of Minnesota Medical School², who will give an overview of the NK cell therapy landscape, discuss current limitations and provide perspective on the future direction of the field as it expands into exciting new therapeutic areas beyond oncology including inflammatory autoimmune indications.

Dr. Miller will elaborate on GT Biopharma’s TriKE^® platform which has created an extensive pipeline of NK cell engagers. He will define where these engagers may best fit into the broader therapeutic landscape. Dr. Juckett will speak to GT Biopharma’s Phase 1 trial expected to start in Q4 evaluating GTB-3650 monotherapy for the treatment of acute myeloid leukemia (AML).

A live question and answer session will follow the formal presentation.

1. Dr. Miller is the Consulting Senior Medical Director at GT Biopharma and holds stock and options in GTBP.
2. The University of Minnesota, pursuant to its license agreement with GT Biopharma, is entitled to receive royalties should commercial sales of GTB-3650 be realized. This interest has been reviewed and managed by the University of Minnesota in accordance with its conflict of interest policies.